Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Invested Capital (2016 - 2025)

Historic Invested Capital for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to -$524.3 million.

  • ImmunityBio's Invested Capital fell 52677.87% to -$524.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$524.3 million, marking a year-over-year decrease of 52677.87%. This contributed to the annual value of $202.4 million for FY2024, which is 211679.95% up from last year.
  • As of Q3 2025, ImmunityBio's Invested Capital stood at -$524.3 million, which was down 52677.87% from -$570.7 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Invested Capital peaked at $202.4 million during Q4 2024, and registered a low of -$697.4 million during Q2 2024.
  • For the 5-year period, ImmunityBio's Invested Capital averaged around -$295.4 million, with its median value being -$337.6 million (2022).
  • As far as peak fluctuations go, ImmunityBio's Invested Capital tumbled by 95430.24% in 2021, and later skyrocketed by 211679.95% in 2024.
  • Quarter analysis of 5 years shows ImmunityBio's Invested Capital stood at -$243.9 million in 2021, then surged by 92.65% to -$17.9 million in 2022, then skyrocketed by 43.99% to -$10.0 million in 2023, then skyrocketed by 2116.8% to $202.4 million in 2024, then plummeted by 359.04% to -$524.3 million in 2025.
  • Its last three reported values are -$524.3 million in Q3 2025, -$570.7 million for Q2 2025, and $84.6 million during Q1 2025.